Manhattan Scients
Manhattan Scientifics, Inc., a technology incubator, engages in the acquisition, development, and commercialization of life-enhancing technologies in the United States. It develops technologies in the areas of nano-technologies and nano-medicine. The company also offers nanostructured bulk metals and alloys in the form of rod, bar, wire, and foil for medical implants and other applications. The c… Read more
Manhattan Scients (MHTX) - Total Assets
Latest total assets as of June 2024: $74.00K USD
Based on the latest financial reports, Manhattan Scients (MHTX) holds total assets worth $74.00K USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Manhattan Scients - Total Assets Trend (1999–2023)
This chart illustrates how Manhattan Scients’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Manhattan Scients - Asset Composition Analysis
Current Asset Composition (December 2023)
Manhattan Scients's total assets of $74.00K consist of 21.8% current assets and 78.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2023)
This chart illustrates how Manhattan Scients's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Manhattan Scients's current assets represent 21.8% of total assets in 2023, a decrease from 40.3% in 1999.
- Cash Position: Cash and equivalents constituted 21.2% of total assets in 2023, down from 31.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 57.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Manhattan Scients Competitors by Total Assets
Key competitors of Manhattan Scients based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Manhattan Scients - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Manhattan Scients generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Manhattan Scients is currently not profitable relative to its asset base.
Manhattan Scients - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.03 | 0.22 |
| Quick Ratio | 0.02 | 0.03 | 0.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.37 Million | $ -1.79 Million | $ -1.56 Million |
Manhattan Scients - Advanced Valuation Insights
This section examines the relationship between Manhattan Scients's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.64 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -69.4% |
| Total Assets | $316.00K |
| Market Capitalization | $47.42K USD |
Valuation Analysis
Below Book Valuation: The market values Manhattan Scients's assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Manhattan Scients's assets decreased by 69.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Manhattan Scients (1999–2023)
The table below shows the annual total assets of Manhattan Scients from 1999 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $316.00K | -69.35% |
| 2022-12-31 | $1.03 Million | -70.15% |
| 2021-12-31 | $3.45 Million | -49.56% |
| 2020-12-31 | $6.85 Million | +207.78% |
| 2019-12-31 | $2.23 Million | -16.35% |
| 2018-12-31 | $2.66 Million | -75.47% |
| 2017-12-31 | $10.85 Million | +42.06% |
| 2016-12-31 | $7.63 Million | -40.67% |
| 2015-12-31 | $12.87 Million | +254.23% |
| 2014-12-31 | $3.63 Million | +95.22% |
| 2013-12-31 | $1.86 Million | +0.43% |
| 2012-12-31 | $1.85 Million | -11.97% |
| 2011-12-31 | $2.10 Million | +9.24% |
| 2010-12-31 | $1.93 Million | +116.52% |
| 2009-12-31 | $890.00K | -12.66% |
| 2008-12-31 | $1.02 Million | +41.14% |
| 2007-12-31 | $722.00K | +21.55% |
| 2006-12-31 | $594.00K | -49.23% |
| 2005-12-31 | $1.17 Million | -10.21% |
| 2004-12-31 | $1.30 Million | +6.37% |
| 2003-12-31 | $1.23 Million | -25.58% |
| 2002-12-31 | $1.65 Million | -43.18% |
| 2001-12-31 | $2.90 Million | -21.36% |
| 2000-12-31 | $3.68 Million | -1.23% |
| 1999-12-31 | $3.73 Million | -- |